CVM Cel Sci Corp

Price (delayed)

$1.62

Market cap

$28.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.69

Enterprise value

$27.54M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6

CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with ...

Highlights
Cel Sci's quick ratio has soared by 138% YoY and by 98% from the previous quarter
The company's EPS has surged by 82% YoY and by 21% QoQ

Key stats

What are the main financial stats of CVM

CVM stock price

How has the Cel Sci stock price performed over time
Intraday
-1.82%
1 week
1.25%
1 month
29.6%
1 year
-86.31%
YTD
-69.2%
QTD
55.77%

Financial performance

How have Cel Sci's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.31M
Net income
-$22.7M
Gross margin
N/A
Net margin
N/A
CVM's net income is up by 11% year-on-year
Cel Sci's operating income has increased by 10% YoY

Price vs fundamentals

How does CVM's price correlate with its fundamentals

Growth

What is Cel Sci's growth rate over time

Valuation

What is Cel Sci stock price valuation
P/E
N/A
P/B
1.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 82% YoY and by 21% QoQ
The stock's price to book (P/B) is 73% less than its 5-year quarterly average of 4.8 and 60% less than its last 4 quarters average of 3.2
The equity has soared by 59% from the previous quarter and by 56% YoY

Efficiency

How efficient is Cel Sci business performance
CVM's return on equity is up by 22% year-on-year and by 9% since the previous quarter
Cel Sci's return on invested capital has decreased by 21% YoY and by 8% QoQ
The return on assets has grown by 6% year-on-year

Dividends

What is CVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CVM.

Financial health

How did Cel Sci financials performed over time
The total assets is 105% more than the total liabilities
Cel Sci's current ratio has soared by 147% from the previous quarter
Cel Sci's quick ratio has soared by 138% YoY and by 98% from the previous quarter
CVM's debt is 28% smaller than its equity
The equity has soared by 59% from the previous quarter and by 56% YoY
The company's debt to equity fell by 49% YoY and by 42% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.